Antigon | Team
page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,ajax_updown,page_not_loaded,,vertical_menu_enabled, vertical_menu_transparency vertical_menu_transparency_on,qode-title-hidden,paspartu_enabled,paspartu_on_top_fixed,paspartu_on_bottom_fixed,vertical_menu_inside_paspartu,side_area_uncovered_from_content,footer_responsive_adv,transparent_content,qode-child-theme-ver-1.0.0,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

Thierry Baltus is an Entrepreneur-Consultant in Biotechnology and Medical Device, with a Master of Business Administration from HEC-ULg University.

He has an extensive experience (over 20 years) in the pharmaceutical and medical device industry at the Sales & Marketing/Business Development level in Europe and the United States. Through various key managerial positions, he has also assumed responsibility for the multifunctional coordination (R&D, Regulatory, Clinical, Manufacturing, Supply, Legal) of the development and commercial launch of several drugs and medical devices worldwide.

As a consultant, he has carried out assignments, on behalf of startup companies, in the areas of Pharma/Biotech, Digital/EEG apps/device, Home Medical Services, IVD device, Radiology equipment and Transfusion device,

He currently holds the position of CEO and co-founder of Antigon sa, a MedTech startup spin-off company from ULB University, founded in 2016, in the Immuno-Hematology-Transfusion field, which is developping a POCT IVD medical device, based on proprietary disruptive technology, aiming to improve Transfusion safety.


Francis Corazza, MD, PhD, Professor of haematology and immunopathology, faculties of Pharmacy and Medicine, “Université Libre de Bruxelles” (ULB), is Chief of the Department of Immunology at the Laboratory of Brussels University Hospitals (LHUB-ULB). He is also director of the Laboratory of translational research at the Brugmann University Hospital, ULB, Brussels.

During the past 20 years, his research activities have been focused on human blood cell phenotypic and functional analysis and pathophysiology of inflammation and immune diseases. He also contributed to development and validation of biomarkers of autoimmune and allergic diseases. He is author and co-author of about 80 publications in international peer-reviewed scientific journal.


Hanane El Kenz, PharmD, PhD, Associate Professor of Immunohaematology and blood banking, is the head of the laboratory of immunohematology and the blood bank at Brugmann University Hospital and Queen Elisabeth Children University Hospital, Université Libre de Bruxelles (ULB).

Since 15 years her clinical and research activities have been devoted to many aspects of transfusion safety improvement. In the framework of her doctoral thesis, she developed and validated a method allowing bedside determination of the blood group. She also focused during the past 5 years on the genotyping of erythrocyte blood group antigens as a tool for improving transfusion management. She is a member of expert committees for immunohematology.